ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV

ACTG A5095 - HIV 初始治疗的蛋白酶抑制剂保留方案

• 批准号: 7377775
• 负责人: THOMAS A CAMPBELL
• 金额: $ 0.27万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377775
• 关键词: ACTG; A5095; PROTEASE; INHIBITOR; SPARING

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to learn how well each combination of drugs lowers the amount of HIV in the blood and keeps it low and how well the drug combinations are tolerated and if they are safe. Subjects must be never have taken anti-HIV drugs, and have a viral load greater than 400 copies. Subjects will be randomized by chance to one of the following treatment groups: Group A: ABC+3TC+ZDV combination tablet 3TC+ZDV placebo tablet (no active drug) EFV capsules once daily; Group B: ABC+3TC+ZDV combination tablet 3TC+ZDV placebo tablet EFV placebo capsules; Group C: ABC+3TC+ZDV placebo 3TC+ZDV combination tablet EFV capsules. This study lasts about 3.5 years.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。这项研究的目的是了解每种药物组合如何降低血液中的艾滋病毒含量并使其保持在低水平，以及药物组合的耐受性如何以及它们是否安全。受试者必须从未服用过抗HIV药物，并且病毒载量大于400拷贝。受试者将随机分配至以下治疗组之一：A组：ABC+3 TC +ZDV复方片剂3 TC + ZDV安慰剂片剂（无活性药物）EFV胶囊，每日一次; B组：ABC+3 TC +ZDV复方片剂3 TC + ZDV安慰剂片剂EFV安慰剂胶囊; C组：ABC+3 TC +ZDV安慰剂3 TC + ZDV复方片剂EFV胶囊。这项研究持续了大约3.5年。